Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?

doi:10.1016/j.jval.2010.10.012

Value in Health

Volume 14, Issue 1, January–February 2011, Pages 160-165

https://doi.org/10.1016/j.jval.2010.10.012 Get rights and content

Under an Elsevier user license

open archive

Abstract

Objective

To assess the convergent and discriminative validity of the Health Utilities Index Mark 3 (HUI-3) for patients with ankylosing spondylitis (AS).

Methods

Data were derived from the Adalimumab Trial evaluating Long-term efficacy and safety for Ankylosing Spondylitis (ATLAS). The study team specified 90 a priori hypotheses regarding the direction and magnitude of the expected associations between the overall and single-attribute scores of the HUI-3 and other health status and quality-of-life measures: Short Form 36 Health Survey (SF-36), Ankylosing Spondylitis Quality-of-Life Questionnaire, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Metrology Index, and Patient's and Physician's Global Assessments of Disease Activity. With baseline data, correlation coefficients were calculated and interpreted according to the guidelines suggested by Guyatt for negligible (0–0.19), weak (0.20–0.34), moderate (0.35–0.50), and strong (>0.5) associations. The a priori hypotheses were tested using Pearson's correlation coefficients.

Results

A total of 315 patients with active AS were randomized and enrolled in ATLAS. The correlation coefficients between the HUI-3 scores and other health-related quality-of-life instruments confirmed 61.1% of the a priori hypotheses, with an additional 35.5% being under- or overestimated by one correlation category.

Conclusion

These results provide evidence of the cross-sectional, convergent, and discriminative validity of the HUI-3 for deriving utility scores in patients with AS.

Keywords

Ankylosing spondylitis (AS)

Health-related quality of life (HRQoL)

Health utilities index mark 3 (HUI-3)

Validation

Cited by (0)

: Funding: Funding for this study was provided by Abbott Laboratories, Abbott Park, IL, USA. Conflicts of interest: Katherine Gooch, Aileen Pangan, and Hartmut Kupper are employees of Abbott Laboratories. Robert Wong was an employee of Abbott at the time these analyses were conducted. David Feeny has a proprietary interest in Health Utilities Incorporated (HUInc.), Dundas, Ontario, Canada. HUIinc. distributes copyrighted Health Utilities Index (HUI) material and provides methodological advice on the use of HUI. Dennis Revicki has received research funding and consulting fees from Abbott Laboratories. Desiree van der Heijde has served as a consultant for Abbott, Amgen, Aventis, Bristol Myers Squibb, Centocor, Pfizer, Roche, Schering Plough, UCB, and Wyeth.